Long-Lasting Rituximab-Induced Reduction of Specific—But Not Total—IgG4 in MuSK-Positive Myasthenia Gravis

Overview of attention for article published in Frontiers in immunology, May 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet

policy: 1 policy source

Citations

dimensions_citation: 51 Dimensions

Readers on

mendeley: 38 Mendeley

Summary News Policy documents Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Rituximab for the Treatment of Myasthenia Gravis: A 2021 Update

Cited by Canadian Agency for Drugs and Technologies in Health on 15 Apr 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.